Tralokinumab Medicine 09 January 2018 Extended indication Severe asthma in adults and adolescents inadequately controlled on ICS + LABA. Therapeutic value No judgement Total cost Registration phase Withdrawn Product Active substance Tralokinumab Domain Lung diseases Reason of inclusion Main indication Asthma Extended indication Severe asthma in adults and adolescents inadequately controlled on ICS + LABA. Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer AstraZeneca Portfolio holder Mechanism of action Unknown Route of administration Unknown Therapeutical formulation Unknown Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Registration Registration route Unknown Type of trajectory Unknown Particularity New medicine ATMP Unknown Submission date Expected Registration Orphan drug Unknown Registration phase Withdrawn Reimbursement Medicine sluice Additional remarks Ontwikkeling voor deze indicatie is stopgezet door AstraZeneca (feb 2018). Therapeutic value Current treatment options Therapeutic value No judgement This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks